Sanofi diabetes med offers freer schedule

Share this article:

New Phase-IIIb data about Sanofi's diabetes drug Lyxumia (lixisenatide) show that the drug may have flexible dosing on its side. The drug met the target of “non-inferiority in blood-sugar lowering” regardless of whether it was taken before breakfast or during what Sanofi calls “the main meal of the day,” which ended up being lunch for 53% of the patients in the 451-person clinical trial.

The daily GLP-1 injection is already marketed in Europe, Mexico, Australia and Japan, among other countries, but is in waiting mode in the US. The company pulled its FDA review request in September, saying it wanted its Elixa cardiovascular study to be completely wrapped before offering the drug up for US regulatory review.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.